TRCT
RCEL icon

Tower Research Capital (TRC)’s Avita Medical RCEL Stock Holding History

Tower Research Capital (TRC)’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.39K Sell
2,273
-1,756
-44% -$7.57K ﹤0.01% 4028
2026
Q1 		$14.9K Buy
4,029
+717
+22% +$3.01K ﹤0.01% 3687
2025
Q4 		$11.4K Sell
3,312
-2,950
-47% -$11.8K ﹤0.01% 3597
2025
Q3 		$32K Buy
6,262
+2,103
+51% +$11K ﹤0.01% 2888
2025
Q2 		$22K Buy
4,159
+2,712
+187% +$19.7K ﹤0.01% 3626
2025
Q1 		$11.8K Sell
1,447
-277
-16% -$2.59K ﹤0.01% 3505
2024
Q4 		$22.1K Buy
1,724
+271
+19% +$3.2K ﹤0.01% 3112
2024
Q3 		$15.6K Sell
1,453
-3,548
-71% -$33.3K ﹤0.01% 3407
2024
Q2 		$39.6K Buy
5,001
+4,753
+1,917% +$45.2K ﹤0.01% 3273
2024
Q1 		$3.98K Sell
248
-7,097
-97% -$115K ﹤0.01% 4760
2023
Q4 		$101K Buy
7,345
+6,797
+1,240% +$77.9K ﹤0.01% 2640
2023
Q3 		$8.01K Sell
548
-76
-12% -$1.29K ﹤0.01% 4408
2023
Q2 		$10.6K Buy
+624
New +$9.16K ﹤0.01% 4094
2023
Q1 		– Sell
-3,464
Closed -$23K – 6194
2022
Q4 		$23K Buy
3,464
+1,845
+114% +$11.1K ﹤0.01% 3003
2022
Q3 		$9K Sell
1,619
-9,774
-86% -$60.4K ﹤0.01% 4682
2022
Q2 		$54K Buy
11,393
+10,415
+1,065% +$64.3K ﹤0.01% 2809
2022
Q1 		$8K Sell
978
-943
-49% -$8.69K ﹤0.01% 4611
2021
Q4 		$23K Sell
1,921
-1,341
-41% -$20.4K ﹤0.01% 3524
2021
Q3 		$58K Buy
3,262
+2,183
+202% +$41.2K ﹤0.01% 2829
2021
Q2 		$22K Buy
+1,079
New +$21.3K ﹤0.01% 3812
2021
Q1 		– Sell
-654
Closed -$12K – 5660
2020
Q4 		$12K Sell
654
-1,044
-61% -$22.9K ﹤0.01% 4209
2020
Q3 		$43K Buy
1,698
+1,422
+515% +$35.4K ﹤0.01% 3597
2020
Q2 		$8K Buy
+276
New +$8.44K ﹤0.01% 4117

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s RCEL Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Avita Medical (RCEL) stake by 44% in Q2 2026, selling an estimated $7.57K and leaving 2,273 shares worth $9.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

Tower Research Capital (TRC) first reported a position in RCEL in Q2 2020 and has held it in 23 quarters since. The position peaked at $101K in Q4 2023. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Tower Research Capital (TRC) held 2,273 shares of Avita Medical worth $9.39K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,756 Avita Medical shares in Q2 2026, an estimated $7.57K.
  • Avita Medical made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4028 holding.
  • Tower Research Capital (TRC) first reported a position in Avita Medical in Q2 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Avita Medical position peaked at $101K in Q4 2023.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.